Physician profile
Mark Goldstein
NPI 1649216342
$21,202.10
in general payments reported to CMS, 2019-2025
88 companies · $3,623 in 2025
The $3,623 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $468 · 2021: $1,791 · 2022: $2,314 · 2023: $3,113 · 2024: $9,783 · 2025: $3,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $5,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,584.68 |
| Consulting Fee | $5,934.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $6,303.73 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $1,423.09 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $1,316.30 | 2020-2025 | Tezspire, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $1,136.04 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $893.33 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $632.95 | 2020-2025 | |
| Celgene Corporation | $462.30 | 2020-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $436.79 | 2023-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $416.68 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Astellas Pharma US INC | $416.58 | 2021-2025 | Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $363.23 | 2020-2025 | Hyqvia, Ninlaro |
| Pharmaessentia USA Corporation | $357.00 | 2022-2025 | Besremi |
| Abbvie INC. | $352.37 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $305.60 | 2020-2025 | Opdivo, Reblozyl |
| Genzyme Corporation | $282.70 | 2022-2025 |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $276.62 | 2020-2023 | Lumakras, Xgeva, Nplate |
| Seagen INC. | $263.83 | 2020-2023 | Tukysa, Padcev, Tivdak |
| Regeneron Healthcare Solutions, INC. | $251.77 | 2021-2025 | Libtayo |
| Kite Pharma, INC. | $249.29 | 2020-2025 | Yescarta |
| Eisai INC. | $241.16 | 2020-2025 | |
| Incyte Corporation | $232.71 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $198.93 | 2020-2023 | Epkinly, Imbruvica |
| Glaxosmithkline, LLC. | $195.52 | 2019-2025 | Zejula, Jemperli |
| Puma Biotechnology, INC. | $188.16 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $180.78 | 2022-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $178.84 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Beone Medicines USA, INC. | $175.71 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $164.22 | 2020-2024 | Brukinsa |
| Exelixis INC. | $158.74 | 2021-2025 | Cabometyx |
| Tg Therapeutics, INC. | $157.65 | 2021 | |
| Array Biopharma INC | $146.13 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Taiho Oncology, INC. | $131.23 | 2022-2025 | |
| Emd Serono, INC. | $126.08 | 2020-2025 | |
| Gilead Sciences, INC. | $121.84 | 2025 | Yeztugo |
| Alexion Pharmaceuticals, INC. | $118.10 | 2023-2025 | Ultomiris |
| Myovant Sciences INC. | $103.65 | 2021 | |
| Mirati Therapeutics, INC. | $93.53 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $92.19 | 2023-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $91.87 | 2024-2025 | |
| Acrotech Biopharma INC. | $91.10 | 2021-2025 | Beleodaq |
| Aadi Bioscience, INC. | $90.28 | 2023 | Fyarro |
| Janssen Pharmaceuticals, INC | $77.29 | 2022-2024 | Xarelto |
| Lilly USA, LLC | $76.56 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Adaptive Biotechnologies Corporation | $75.89 | 2022-2025 | Clonoseq |
| Agios Pharmaceuticals, INC. | $74.67 | 2024 | Pyrukynd |
| Eusa Pharma (US) LLC | $71.84 | 2021-2022 | |
| G1 Therapeutics, INC. | $71.43 | 2022-2023 | Cosela |
| Sobi, INC | $67.58 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $65.15 | 2020-2025 | Onivyde, Somatuline Depot |
| Tersera Therapeutics LLC | $61.05 | 2024-2025 | Quzyttir, Xermelo |
| Syndax Pharmaceuticals, INC. | $60.51 | 2025 | |
| Deciphera Pharmaceuticals INC. | $60.45 | 2024-2025 | Qinlock, Romvimza |
| Ge Healthcare | $59.97 | 2022 | |
| Progenics Pharmaceuticals, INC. | $59.31 | 2022 | |
| Coherus Oncology, INC. | $57.58 | 2022-2024 | |
| Blueprint Medicines Corporation | $53.15 | 2021-2024 | Ayvakit |
| Stemline Therapeutics INC. | $49.46 | 2024-2025 | Orserdu |
| Azurity Pharmaceuticals, INC. | $47.07 | 2024-2025 | Danziten, Vivimusta |
| Tactile Systems Technology INC | $46.74 | 2025 | Flexitouch Plus, Nimbl |
| Portola Pharmaceuticals, LLC | $44.72 | 2019 | |
| Myriad Genetic Laboratories, INC. | $42.05 | 2024 | Myrisk |
| Pharmacosmos Therapeutics INC. | $40.98 | 2022-2024 | Monoferric |
| Secura Bio, INC. | $37.77 | 2022-2024 | Copiktra |
| Servier Pharmaceuticals LLC | $37.25 | 2022 | |
| Janssen Scientific Affairs, LLC | $34.42 | 2023 | Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.43 | 2022 | |
| Novocure INC. | $29.42 | 2025 | Optune Lua (Novottf-200t) |
| Immunocore Limited | $27.14 | 2025 | Kimmtrak |
| Globus Medical, INC. | $25.27 | 2025 | Senza |
| Heron Therapeutics, INC. | $23.69 | 2022 | |
| Global Blood Therapeutics, INC. | $22.18 | 2022 | |
| Dendreon Pharmaceuticals LLC | $21.93 | 2020 | |
| Adc Therapeutics America, INC. | $21.49 | 2025 | |
| Sun Pharmaceutical Industries INC. | $20.34 | 2025 | |
| Medtronic USA, INC. | $20.33 | 2019 | |
| Karyopharm Therapeutics INC. | $20.11 | 2023 | Xpovio |
| Tolmar Pharmaceuticals, INC. | $19.92 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.69 | 2025 | Givlaari |
| Morphosys, US INC. | $19.67 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $19.01 | 2024 | Ogsiveo |
| Zimmer Biomet Holdings, INC. | $16.72 | 2024 | |
| Foundation Medicine, INC. | $14.67 | 2022 | |
| Cashflow Solutions, LLC | $14.47 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Amag Pharmaceuticals, INC. | $12.33 | 2022 | |
| Emmaus Medical, INC. | $11.78 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $671Enhertu $406Tezspire $371Darzalex $349Pluvicto $322Epkinly $320Padcev $308Besremi $305Tecvayli $291Reblozyl $242Xtandi $226Imbruvica $225Lynparza $212Libtayo $211Erleada $205Lutathera $201Kisqali $198Talvey $197Sarclisa $173Scemblix $168Lenvima $167Rybrevant $163Venclexta $159Jemperli $153Zejula $153Fabhalta $151Xt Cdx $149Yescarta $148Brukinsa $138Polivy $137Lunsumio $137Rezlidhia $137Tavalisse $137Welireg $132Yeztugo $122Cabometyx $119Ultomiris $118Fotivda $118Lonsurf $112Inqovi $112Monjuvi $107Braftovi $103Lorbrena $99.41Krazati $93.53Tivdak $93.38Xofigo $91.87Nubeqa $91.87Jakafi $90.92Fyarro $90.28Hyqvia $90.07Columvi $83.75Talzenna $82.87Opdivo $82.61Piqray $82.12Pomalyst $81.43Orgovyx $80.96Imfinzi $76.17Pyrukynd $74.67Mektovi $74.48Oxbryta $73.52Calquence $72.22Beleodaq $68.84Ibrance $68.53Pemazyre $67.95Tukysa $62.02Ayvakit $61.38Qinlock $60.45Jaypirca $60.44Verzenio $60.44Tabrecta $60.39Inlyta $59.70Tevimbra $58.71Keytruda Qlex $58.52Nerlynx $56.93Xarelto $53.99Injectafer $53.50Akeega $51.90Orserdu $49.46Cosela $47.15Onivyde $46.95Tasigna $46.89Doptelet $46.79Flexitouch Plus $46.74Nimbl $46.74Lumakras $45.22Clonoseq $44.51Myrisk $42.05Quzyttir $40.81Nplate $39.86Xgeva $39.86Retevmo $39.84Udenyca $37.32Cablivi $35.18Elrexfio $34.85Adcetris $34.85Elahere $32.09Optune Lua (Novottf-200t) $29.42Ninlaro $28.04Kimmtrak $27.14Gazyva $26.88
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.